Background The endogenous nucleoside adenosine plays an important role in the regulation of vascular tone, especially during ischemia. Experimental data derived from animal m od els suggest that nitric oxide (NO) contributes to the vasodilator effect of adenosine. The primary purpose of this investigation was to determine whether the endothelial release of NO contributes to adenosine-induced vasodilation in humans.
A part from its role as a constituent of the intra cellular energy source ATP, the endogenous nucleoside adenosine also has important ef fects in the extracellular compartment. In the cardiovas cular system, extracellular adenosine is a regulatory substance, matching blood flow 'to alterations in tissue oxygen supply or demand.1 Until recently, the vasodila tor effect of adenosine was thought to be based on direct stimulation of A2-adenosine receptors on vascular smooth muscle cells, which mediate an increase in the second messenger cAMP by stimulating adenylate cy clase. Therefore, this agent has been used frequently in animal as well as human studies to evaluate endotheli um-independent vasodilation.2* 3 However, recent inves tigations have disputed the endothelium-independent character of adenosine-mediated vasodilation. Several vascular preparations have shown attenuated responses to adenosine or adenosine analogues after previous inhibition of endothelial NO synthesis4,5 or after rubbing of the endothelium.6"8 Also, infusion of large adenosine agonists (M'-octylamine adenosine coupled to carboxylated latex microspheres), which were assumed to be confined to the intravascular space, induced an obvious decrease in coronary vascular resistance in the salineperfused guinea pig heart, presumably by means of an endothelium-derived mechanism.9 Moreover, functional adenosine receptors have been identified on the endo thelium, even in human aortic endothelial cells. 7 Several potential mechanisms could mediate the en dothelial release of NO during adenosine administra tion. Stimulation of endothelial adenosine receptors may mobilize calcium and thereby activate endothelial NO synthase.U ) Adenosine A {-receptors have been demon strated to be coupled to ATP-dependent potassium channels by guanine nucleotide binding proteins, in particular by the G«| proteins. 11 The Gaj proteins can mobilize calcium by stimulating phosphoinositide-spe cific phospholipase C activity, causing hydrolysis of phosphatidylinositol 4,5-diphosphate. 12 Also, adenosine can stimulate the endothelial influx of calcium and thereby NO synthesis by activating ATP-dependent po tassium channels and hyperpolarizing endothelial 2136 Circulation Vol 92, No 8 October 15, 1995 Selected Abbreviations and Acronyms FBF = forearm blood flow L-NMMA = À^-monomethyl-L-arginine NO = nitric oxide SNP = sodium nitroprusside cells.13* 14 In addition, potassium channel activation and NO release can be triggered nonspecifically by incre ments in shear stress related to the raised flow. 15 In the present study we evaluated whether the endo thelial release of NO plays an important role in the vasodilating effects of adenosine in humans and, if it does, whether the aforementioned potential mecha nisms are involved in that NO release. H um an data on this subject are especially im portant given the large interspecies differences in endothelial pharmacology. 16 To address these questions, the effects of adenosine were assessed in vivo by use of the perfused forearm technique, both before and during blockade of the production of NO by the NO synthase inhibitor L-NMMA and before and during blockade of potassium channels by the sulfonylurea derivative tolbutamide and the antiarrhythmic drug quinidine. These studies, as well as appropriate control experiments, allow us to conclude that the vascular effects of adenosine in humans are based, at least in part, on the endothelial release of NO. This adenosine-induced release of NO is not mediated by activation of ATP-dependent potassium channels or by quinidine-sensitive potassium channels.
Methods
Thirty-nine healthy volunteers participated in the study, and all gave written informed consent before participation. The health status of each volunteer was determined by medical history and a physical examination as well as by laboratory investigations to assess lipid levels. Demographic data of the participants are shown in Table 1 . Subjects who had high blood pressure (>145/90 mm Hg) or high concentrations of serum cholesterol (LDL greater than the 75th percentile for age and sex) or who smoked cigarettes were excluded from participa tion because these features can interfere with the NO pathway.17 '20 Each subject participated in one experiment of approxi mately 4 hours5 duration, The experiments were performed in a quiet, temperature-controlled room (22°C). The participants were all asked to abstain from food, alcohol, and caffeine for at least 12 hours before the test. Because caffeine acts as a potent adenosine receptor antagonist in the human cardiovascular system,21 we measured plasma caffeine levels at the time of the test to ensure compliance with respect to the abstinence recommendations. The subjects remained in the supine posi tion throughout the test. After each subject's arrival in the laboratory, the left brachial artery was cannulated under local anesthesia with a 20-gauge catheter, which was used for intraarterial drug infusion as well as for blood pressure monitoring (Gould Inc). Drugs were delivered with an automatic syringe infusion pump (Harvard Apparatus).
FBF recordings were started after an equilibration period of at least 40 minutes. FBF was measured in each arm by venous occlusion mercury-in-Silastic stram-gauge plethysmography (Hokanson EC4, D.E. Hokanson) as previously described. 19 Both arms rested in slings at heart level, with the forearms slightly elevated to ensure a sufficient venous return. To be sure that FBF recordings referred predominantly to the forearm skeletal muscle circulation, the hand circulation was occluded during all FBF recordings by a wrist cuff inflated 100 mm Hg above the systolic blood pressure.22
Assessment of the Role of NO in the Vasodilator Response to Adenosine and Verapamil
In the first subgroup of six subjects, the vasodilator response to increasing dosages of adenosine was investigated. Baseline measurements were taken during infusion of placebo (glucose 5%) into the brachial artery. Adenosine was then infused intraarterially in six increasing dosages for 4 minutes per dose (adenosine dosages were 1.5, 5, 15, 50, 150, and 500 /¿g/min). Measurements were performed during the last 2 minutes of each infusion. After an equilibration interval of 60 minutes in which the FBF was allowed to return towards baseline levels, new baseline recordings were obtained during placebo infu sion. Subsequently, infusion of L-NMMA into the brachial artery was started at a dose of 2 mg/min. After 15 minutes of the L-NMMA-infusion alone, hemodynamic measurements were taken to evaluate the vasoactive effects of L-NMMA. Thereafter, the six increasing adenosine dosages were again administered and coinfused with L-NMMA. The total duration of L-NMMA infusion was approximately 40 minutes. In an additional series of three subjects, we verified that infusion of L-NMMA at 2 mg/min for 40 minutes induced a steady-state vasoconstrictor response that did not progress over time.
In the next group of six subjects, similar experiments were performed with a similar time schedule and drug dosages of adenosine and L-NMMA, but with these experiments the L-NMMA infusion was accompanied by a low intra-arterial dose of the NO donor SNP. Previous studies have shown that L-NMMA infusion induces a vasoconstrictor response in the forearm vascular bed by inhibiting the basal release of NO from the endothelium.23 From a methodological viewpoint, this change in baseline could complicate the interpretation of the results, given that the baseline vascular resistance is an impor tant determinant of the response to a vasodilator stimulus24 and that the achieved concentrations of adenosine are propor tionally higher in a vasoconstricted state. From pilot studies, we determined that an intra-arterial dose of SNP of 0.2 fxg/min was appropriate to counteract the vasoconstrictor response to L-NMMA. Therefore, this dose of SNP was coinfused with L-NMMA. The "clamping" of the NO-mediated vascular tone by the concomitant infusion of L-NMMA and SNP has recently been shown to be a useful approach in animal experiments on this subject. 25 An additional six subjects were studied for reasons of time control. The same time schedule was used as in the other adenosine experiments; however, the second dose-response measurement was performed in the presence of placebo in stead of active drug. This study was done to ensure that the forearm vasodilator response to adenosine did not change over the 4-hour experimental session.
In theory, NO release from the endothelium may have been triggered nonspecifically by the adenosine-induced increase of shear stress resulting from the high FBFs. To evaluate this nonspecific stimulus of NO release, we measured FBF re sponses to the endothelium-independent calcium entry blocker verapamil before and after L-NMMA (2 mg/min) in another six subjects. Verapamil was used in four dose-steps of 5 minutes each (10, 30, 100, 300 ¡jlg/min). Because verapamil has a longer half-life than adenosine, we waited for 90 minutes to wash out the drug after the first series of verapamil infusion. Apart from these details, the time schedule was similar to that used in the previous experiments.
Assessment of the Role of Potassium Channel Activation in the Vasodilator Response to Adenosine
It recently was shown that adenosine receptors are coupled to ATP-dependent potassium channels.11 These channels can be blocked specifically by sulfonylurea derivatives, not only in the pancreatic j3 cells but also at the level of the vessel wall.26 Therefore, adenosine dose-response studies were performed in a fifth group of six volunteers before and during the intrabrachial infusion of tolbutamide ('1 mg/min). The infusion o f tolbutamide started 15 minutes before the first adenosine dose. Because systemic dosages of tolbutamide may induce hypogly cemia by stimulating insulin release and because insulin in creases skeletal muscle blood flow and alters vascular respon siveness to drugs in the forearm m odel,27-28 arterial blood samples for glucose and insulin were taken just before and after tolbutamide infusion to demonstrate that no systemic effects occurred at this low dose.
In an additional six healthy volunteers, the vascular response to adenosine was assessed before and during the intra-arterial infusion of 0.5 mg/min quinidine. Studies have shown by use of the patch-clamp technique that quinidine blocks several types of potassium channels,29'33 including those activated by aden osine. To limit the cumulative dose of quinidine in healthy volunteers, we used only the four highest adenosine dosages (instead of all six) in these subjects. M easurements of FBF and subsequent administration of the four adenosine dosages were started after 10 minutes of quinidine infusion, and the total infusion time of quinidine was restricted to 30 minutes (cumu lative dose, 15 mg).
Drugs
Adenosine was prepared for each experiment by dilution of Adenocard vials (6 mg per 2 mL, Fujisawa Pharmaceutical Co) in saline. A^-monomethyl-L-arginine acetate, purchased from Calbiochem, was diluted in glucose 5% just before the exper iments. SNP was purchased from Elkins-Sinn, Inc. Protected from light, it was dissolved in glucose 5% just before adminis tration. Verapamil HC1 (American R eagent Laboratories Inc) was diluted with glucose 5%. For the tolbutamide experiments, sterile tolbutamide sodium (Orinase Diagnostic, The Upjohn Co) was dissolved in saline (NaCl 0.9%). For the quinidine studies, we used quinidine gluconate vials (Eli Lilly) of 800 mg/10 mL diluted in glucose 5%. D epending on the experi ment, glucose 5% or saline was used as placebo infusion. All drugs and placebo infusions were administered at the same infusion rate of 0.4 mL/min. 
Statistics and Calculations T he effects of adenosine were analyzed by comparison of the hemodynamic variables at baseline and at the six dosage levels by one-way A N O V A with repeated measures. Post hoc com parisons between the different dosages were made by Scheffe's

Results
Vasodilator Response to Adenosine
For assessment of the vascular response to graded adenosine infusion, the data of the first dose-response curve for all experiments with the six adenosine dosages were pooled (n -2 4 ). Table 2 summarizes the results of this analysis. Adenosine induced a dose-dependent in crease in FBF, which was significantly different from baseline for the third through sixth dosage levels. The dose dependency was supported by significant differ ences between dosages (Scheffé's F tests, Pc.05). One hour after cessation of adenosine infusion, the FBF was identical to the baseline level. As shown in Table 2 , there were no changes in flow in the noninfused forearm or in blood pressure or heart rate during adenosine infusion, arguing against any systemic effect of the dosages used. In the subset of experiments in which the adenosine infusions were repeated after 1 hour without any inter vention (time controls), adenosine increased FBF the first time from 2.3±0.4 to 15.2±4.7 m L 'm in '1 «dL"1 and the second time from 1.9±0,7 to 16.0±7.2 mL*min"1 • dL"1. There was no significant difference between the FBF changes from baseline between the first and second series of measurements.
Plasma caffeine levels could not be detected in 20 of 23 subjects in whom it was measured (lower limit of assay, 0.5 mg/L). In the remaining three subjects, caf feine concentration ranged from 1.8 to 4.0 mg/L. Despite detectable caffeine levels in these three subjects, each showed a vasodilator response to adenosine that was comparable to that observed in the others, justifying inclusion of their data in the results. Moreover, statisti cal analysis after exclusion of these subjects did not affect the outcome of the findings.
Vasoconstrictor Response to L-NMMA
To assess the effect of L-NMMA on basal FBF, the data from six L-NMMA-adenosine experiments, three L-NMMA time-control experiments, and six L-NMMAverapamil experiments were pooled. After 15 minutes of intra-arterial L-NMMA infusion, FBF decreased signif icantly from 2.1±0.2 to 1.5±0.1 m L , min'*1 -dL "1 ( n -1 5 , paired t test: jPc.O'I). In contrast, the FBF of the contralateral noninfused arm remained constant during this infusion (1.8±0.1 before and 1.8±0.1 mL ■ m in "L * dL"1 during L-NMMA infusion). M ore over, L-NM M A infusion did not change the mean arterial blood pressure (81.3±2.3 versus 79.1 ±2.7 mm Hg, P = N S ) or heart rate (56.1 ±2.2 versus 54.9 ±2.1 beats per minute, P=NS), indicating that locai L-NMMA infusion did not affect systemic hemo dynamics. In the three subjects in whom L-NMMA was the only drug given, the FBF fell from 1.8±0.3 m L • m u T 1 ■ dL "1 at baseline to 1.3±0.2 and 1.6±0.1 m L * m in "1 • dL~! after 15 and 40 minutes, respec tively, arguing against a progressive vasoconstrictor effect after 15 minutes of infusion. In the second series of experiments, the vasoconstric tor effect of L-NMMA was counteracted by concomitant infusion of SNP. Again, in the presence of placebo, adenosine caused a dose-dependent forearm vasodilator effect with an increase of FBF from 1.9±0.4 to 14.9±2.0 mL*min~J ■ dL"1 (Fig 2) . A fter conditions returned to baseline, the combined infusion of L-NM M A and SNP did not significantly change FBF (2.0±0.3 versus 2.2±0.3 mL • m in"1 ■ dL"1; n=6, P = N S ). The subsequent admin istration of the six adenosine dosages elicited dosedependent increments in FBF from 2.2±0.3 to 9.8±2,4 mL • min"1 • dL"1; the changes from baseline were signifi cantly reduced compared with those before administration of L-NMMA and SNP (Pc.01) (Fig 2) . No significant changes occurred in contralateral FBF (from. 1.7 ±0,3 mL ■ min-1 • dL"1 at baseline to L8±0.3 mL ■ min"1 -dL"1 at the highest adenosine dose), mean arterial pressure (from 7 9 ± 4 to 8 1 ± 3 mm Hg), or heart rate (from 53±2 to 53±3 beats per minute). Values are shown as mean±SEM. P < .01 for the difference between conditions for these dose responses by repeatedmeasures ANOVA. The intra-arterial infusion of L-NM M A did not change the forearm vasodilator response to verapamil. During placebo, the FBF changes from baseline for the four increasing verapamil dosages averaged 2.3±0.5, 4.2±0.7, 8.6±1.9, and 11.9±2.8 mL * m in"1 * dL"1, whereas these numbers were 1.7±0.2, 3.5±0.9, 6.7±1.4, and 12.2±2.4 mL • m in"1 • d L "1 during concomitant L-NM M A administration. No significant effects on sys temic hemodynamics were observed during the com bined infusion of L-NM M A and verapamil. The con tralateral FBF was 1.9±0.2 mL • m in"1 * dL "1 before and 1.6±0.3 m L ' min"1 * dL-1 during the highest verapamil dose. Respective values for mean arterial blood pressure were 79±2 and 79±2 mm Fig, and for heart rate they were 56±4 and 58±4 beats per minute. Fig 3 demonstrates the effects of tolbutamide on the vasodilator response to adenosine. Tolbutamide infusion into the brachial arteiy did not change the baseline FBF (2.3±0.3 versus 2.2±0.3 m L • m in"1 • dL "1). Moreover, the adenosine-induced increase in FBF was not reduced by tolbutamide. Fig 4 illustrates the effects of quinidine on the forearm vasodilator response to adenosine infusion. In this se ries, adenosine increased FBF from 1.6±0.3 to 9.0±0.8 mL* m in"1 • dL"1. After equilibration, the FBF returned to a baseline value of 1.5 m L * m in"1 * dL"Ten minutes of quinidine infusion increased the baseline FBF signif icantly to 2.9±0,7 m L 'm in " 1 ■ dL "1 (P<.05). However, regional quinidine infusion did not significantly affect the adenosine-induced increase in FBF from baseline.
Effects of NO Synthase Blockade on Vasodilator Responses
Forearm blood flow (ml/min/dl)
Effects of Potassium Channel Blockade on Adenosine Responses
Throughout these two series of experiments, there were no changes in contralateral FBF, blood pressure, or heart rate. The plasma insulin concentrations averaged 4.4 ±1.2 ¿¿U/mL before and 4.5 ±1.2 juAJ/mL after tolbu tamide administration (P=N S), and the glucose levels were 84±3 and 81 ± 2 mg/dL, respectively (P=NS). 
Discussion
The results of this study enable us to conclude that the vasodilator response to adenosine in humans is medi ated, at least in part, by the endothelial release of NO, The following evidence supports this conclusion: (1) blockade of NO synthase by L-NMMA significantly reduced the FBF response to adenosine, (2) the vehiclecontrol experiments ensured that this reduced response could not be attributed to time; and (3) the observation that L-NMMA attenuated adenosine responses could not be attributed to a change in basal vascular resistance, because restoration of baseline conditions by the addi tion of a low dose of SNP did not change the results. We reasoned that the coinfusion of SNP and L-NMMA was the most ideal approach to correct for the L-NM M Aassociated change in baseline vascular resistance. Addi tion of exogenous NO by infusion of SNP was thought to restore the baseline biology of the vascular wall and recondition its responsiveness to vasoactive stimuli. 25 Also, the vasoconstrictor effect of L-NMMA (when infused alone) did not progress over time and thus could not account for the L-NMMA-mediated reduction in adenosine responses. Apart from the pathophysiological consequences of our conclusion, it is obvious that the use of adenosine for the assessment of endothelium-independent vasodilation in peripheral resistance vessels is not a valid approach in human research.
Several recent studies in animals support our obser vations,4'5'8'34 but others do not.2* 35 Species differences and different experimental conditions may contribute to this discrepancy. In the perfused-fore arm technique used in this study, the drug is administered into the vascular lumen, so the exposure to adenosine is much higher for the vascular endothelium than for the under lying smooth muscle cell layer, especially because of the efficient uptake of adenosine by the endothelium.36* 37 In several in vitro vascular preparations, the exposure is more balanced, and therefore direct relaxant effects on smooth muscle cells mediated by stimulation of A 2-adenosine receptors may have been more pronounced.37
Shear Stress as a Mechanism of Action
A number of transducing mechanisms should be con sidered as mediators for the ability of adenosine to release endothelium-derived NO. For example, the aden osine-induced release of NO might have been triggered nonspecifically by the increase in flow (shear stress) rather than by the specific stimulation of endothelial adenosine receptors. However, in previous studies in which the same technique was used, the intra-arterial infusion of L-NMMA reduced the relaxant effects of acetylcholine but not those of SNP, arguing against a contribution of flow-related NO release during druginduced elevations of FBF.38 Furthermore, in the pres ent study, L-NMMA did not attenuate the vasodilator response to the calcium entry blocker verapamil, an endothelium-independent vasodilator, despite produc tion of blood flow responses comparable to those ob served in the middle of the dosage range of adenosine. O ur data therefore point toward a more specific inter action between L-NMMA and adenosine. We and oth ers previously showed that low intrabrachial dosages of the adenosine receptor antagonists caffeine and theo phylline are able to block the forearm vasodilator re sponse to adenosine,21* 39 enabling us to postulate that the adenosine-mediated release of NO results from stimulation of endothelial adenosine receptors. Unfor tunately, selective agonists and antagonists for the dif ferent subtypes of adenosine receptors are not available for human use, so it is not possible at this time to determine whether the adenosine-induced NO release in humans is mediated by stimulation of endothelial A r or A 2"adenosine receptors.
Role of Potassium Channels
We postulated that activation of potassium channels may serve as an intermediate step, transducing stimula tion of adenosine receptors to the synthesis and/or release of NO from the endothelium. Because equipotent dosages of the related sulfonylurea derivative glibenclamide have been shown to attenuate the vasodilator response to pharmacological opening of KA TP channels in the forearm vascular bed,40* 41 we think that our negative observation of tolbutamide cannot be attrib uted to ineffective dosing. Consequently, our data sup port the conclusion that opening of the KATP channel does not contribute to the vasodilator response to intraarterial adenosine infusion in humans. In theory, KATP channel opening might have contributed to the vasoac tive effects of adenosine at two different levels. At the level of the endothelium, KATP channel opening may hyperpolarize endothelial cells, and may thereby activate endothelial NO release by increasing the influx of calci um. 42 In contrast to increases of calcium influx in endothelial cells after hyperpolarization, calcium influx decreases after membrane hyperpolarization in vascular smooth muscle cells.42 Therefore, opening of potassium channels also results in vasodilation at the level of vascular smooth muscle cells. It must be emphasized that because of our intraluminal administration of adenosine, its effects may have been predominantly endothelium dependent, and therefore we think that our tolbutamide data do not exclude a role of KATp channel activation in the smooth muscle-relaxing effects of adenosine. Although we realize that quinidine has several phar macological properties, including sodium channel block ade and antiadrenergic effects, its recently established potassium channel-blocking properties made this drug an additional tool for our study, especially because quinidine was able to attenuate the vasodilator response to adenosine in animal studies.43 Quinidine increased basal FBF but did not attenuate the vasodilator response to adenosine. The effect of quinidine on the baseline flow may well be explained by its a-adrenergic-blocking properties. In line with the reasoning on tolbutamide, our data argue against a role of quinidine-sensitive potassium channels in the adenosine-mediated release of NO but do not exclude an interaction between quinidine and adenosine at the level of vascular smooth muscle cells.
Pathophysiological Implications
Apart from effects on vascular tone, adenosine has other important properties, including inhibition of plate let aggregation,44 inhibition of leukocyte activation,45 and presynaptic inhibition of noradrenaline release. 46 Furthermore, adenosine appears to mediate ischemic preconditioning in the myocardium. 47 The release of endogenous adenosine may also contribute to the reac tive hyperemic response after ischemia14* 48 as well as to exercise-induced vasodilation. 49 In recent years, NO has been demonstrated to affect several of these pathophys iological phenomena in a similar way.14'48'50'53 Because adenosine is released from tissues, including the endo thelium, during anoxia or ischemia,54 the currently ob served relation between adenosine and endothelial NO release makes endogenous adenosine a likely candidate for triggering NO release during ischemia. W e believe that our results create the foundation for future studies on the interrelation between the release of endogenous adenosine and that of NO in several pathophysiological conditions in humans.
